Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Union Budget
Budget 2011-2012 Home
Industry Expectations - Budget 2011-2012
Industry Reactions - Budget 2011-2012
Budget 2010-2011
Budget 2010-2011 Home
Industry Expectations - Budget 2010-2011
Industry Reactions - Budget 2010-2011
Contributor's Corner
Bonanza Portfolio
Hemant K Gupta
Krish Bhatt
S A A R T H I
Trinity Investments
Exchange Information
BSE 2009 Holidays
NSE 2009 Holidays
Investor Guide
Depository & Dematerialisation
Grievance Redressal
Investor Guide
SEBI
Trading of Securities
Transfer of Securities
Your Rights
Budget 2009-2010
Budget 2009-2010 Home
Industry Expectations - Budget 2009-2010
Industry Reactions - Budget 2009-2010
Interim Budget 2009-2010 Home
Industry Expectations - Interim Budget 2009
Budget 2008-2009
Railway Budget 2008-2009
Industry Expectations - Budget 2008
Union Budget 2008-2009
Highlights of Budget 2008-2009
Summary of Budget 2008-2009
Industry Reactions - Budget 2008
IPOs
Current IPOs
Past IPOs
IPO Subscription
Mutual Funds
Gold Exchange Traded Fund
MF Unique Holding
Forthcoming Dividends
ELSS Schemes Comparison
Tax Plans
New Fund Offers
Research
Arbitrages
Equity
Market Whispers
Tax Planning
Home
Equity Linked Savings Scheme
Post Office MIS
9% GOI Senior Citizens Savings Scheme
8% Savings (Taxable) Bonds
Kisan Vikas Patra
National Savings Certificate
Public Provident Fund
Research

| More

Fortis Healthcare - Balance sheet improving, valuations reasonable; upgrade to Hold - Anand Rathi

Posted On: 2013-02-13 20:21:57

Results in line with estimates. Fortis Healthcare's (Fortis) revenue grew 154.5% yoy to Rs. 15.4bn, better than our expected Rs. 14.9bn. Its reported EBITDA margin declined 380bps yoy to 9.9% (versus our estimated 10.3%) on payment of service fees to Religare Health Trust (RHT). The company reported exceptional gain of Rs. 9.7bn, pertaining to gain on dilution of stake in RHT. Adjusting for this gain, the company reported net loss of Rs. 433m.

Healthy growth across segments. Strong revenue growth was largely driven by 20% increase in revenue from India hospitals business with improved EBITDA margin of 15.8%. Domestic diagnostics business (Super Religare Laboratories) grew 12% yoy with 370bps yoy improvement in EBITDA margin to 10.3% (down ~400bps qoq). International business revenue came at Rs. 8.2bn, up 6.4% qoq. EBITDA margin in international business sustained at ~13%.

Our take. We believe that inflow of cash from dilution of stake in RHT, divestment of Dental Corp. subsidiary by Mar'13 and issue of equity shares through the IPP route would help the company strengthen its balance sheet substantially by bringing down D/E level to 0.5x by FY14e. Further, the proportion of revenue from India business would move up to 70%+ from ~50% currently post divestment of Dental Corp., which would bring focus back to India. We maintain revenue estimates, but lower PAT marginally to factor in higher service fees to RHT, which could hit EBITDA. Management focus is currently on strengthening balance sheet and no M&A is expected in near future, which is a positive in our view.

The stock is currently trading at EV/EBITDA valuations of 13.5x FY14e and 10.8x FY15e. We upgrade the stock to Hold from Sell on improving balance sheet and reasonable valuations. We also raise our target price to Rs. 118 (earlier Rs. 110), based on 14x FY14e EBITDA and Rs. 21 for stake in RHT. Risks. Delay in execution of expansion projects and integration of international operations.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com


Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.





Other Headlines:

Technical View on Crude Oil - Target - $ 56 to $ 58 , (CMP - 3640 / $ 54.35): Angel Broking
Ambuja Cements - 4QCY16 Result Update - Better Operating Performance on Higher Realizations - Reliance Securities
Cement - 3QFY17 Results Review - A Quiet Quarter - Impacted by Cash Crunch - Reliance Securities
Britannia Industries - Initiating Coverage - Betting on Premiumization, Distribution and Cost optimization - Reliance Securities
Srikalahasthi Pipes - Initiating Coverage - Piping Gains - Reliance Securities
NCC - Initiating Coverage - A Solid Play in Infrastructure Pickup - Reliance Securities
TCS Buyback - Update - Angel Broking
Nestle India - 4QCY16 Result Update - Better Times Awaited; Maintain REDUCE - Reliance Securities
Kalpataru Power Transmission - 3QFY17 Result Update - Growth Momentum Continues; Strong Order Book Offers High Revenue Visibility - Reliance Securities
NALCO - 3QFY17 Result Update - Strong Performance on Higher Volume, Realizations - Reliance Securities
Further Re-rating of HDFC Bank to come from Core earnings growth: Angel Broking
Cadila Healthcare - no 483 For Moraiya plant: Angel Broking
GlaxoSmithKline Consumer - 3QFY17 Result Update - Weak Demand Accentuated by Demonetization - Reliance Securities
MOIL - 3QFY17 Result Update - Stellar Performance to Continue; Upgrade to BUY - Reliance Securities
Techno Electric & Engineering - 3QFY17 Result Update - Strong Quarter; Order Pipeline Remains Robust - Reliance Securities
J. Kumar Infraprojects - 3QFY17 Result Update - Decent Performance on Execution Ramp-up - Reliance Securities
Views on Sun Pharmaceutical Industries Limited 3QFY2017 Results: Angel Broking
All the queries put to rest at Infosys Press Conference: Angel Broking
Hindustan Zinc - 3QFY17 Result Update - Higher Zinc Prices Aid Earnings, but Valuation Expensive; Reiterate REDUCE - Reliance Securities
Mangalam Cement - 3QFY17 Result Update - Robust Volume Growth Aids Performance - Reliance Securities
Power Grid Corporation - 3QFY17 Result Update - Higher Capitalization Continues to Drive Growth - Reliance Securities
HeidelbergCement - 3QFY17 Result Update - A Quiet Quarter; Expect Improvement Ahead - Reliance Securities
Bank of Baroda - 3QFY17 Result Update - Asset Quality Pressure Continues to Persist; Downgrade to HOLD - Reliance Securities
Steel Authority of India - 3QFY17 Result Update - Higher Raw Material Cost & Lower Volume Dent Margins - Reliance Securities
Hindalco - 3QFY17 Result Update - Strong Performance Continues; Valuation Pricey - Reliance Securities
KNR Constructions - 3QFY17 Result Update - Beats Estimates on Better Execution - Reliance Securities
Ahluwalia Contracts - 3QFY17 Result Update - Strong Performance on All Parameters - Reliance Securities
NBCC - 3QFY17 Result Update - Better Operating Performance; Prospect Remains Bright - Reliance Securities
Goodluck India - 3QFY17 Result Update - Subdued Quarter; Better Times Expected as Input Prices Stabilize - Reliance Securities
Alkem Laboratories - 3QFY2017 Result Update - Angel Broking
Bank Of Baroda - 3QFY2017 Result Update - Angel Broking
Garware Wall Ropes - 3QFY2017 Result Update - Angel Broking
Views on GlaxoSmithKline Pharmaceuticals Limited 3QFY2017 Results: Angel Broking
J.K. Cement - 3QFY17 Result Update - Healthy Operating Performance amid Dismal Volume Growth - Reliance Securities
Jubilant FoodWorks - 3QFY17 Result Update - Too Fast Too Soon; Downgrade to HOLD - Reliance Securities
Sonata Software - 3QFY17 Result Update - Unimpressive Show; IITS Revenue Disappoints - Reliance Securities
JK Lakshmi Cement - 3QFY17 Result Update - Better Operating Performance on Cost Savings - Reliance Securities
Dr. Reddy's Laboratories - 3QFY17 Result Update - Long-term Fundamentals Remain Intact; Headwinds to Persist in the Near-term - Reliance Securities
Titan Company - 3QFY17 Result Update - Dazzles in Dark Times - Reliance Securities
Union Bank of India - 3QFY17 Result Update - Asset Quality Pressure Persists; Downgrade to HOLD - Reliance Securities
Ramco Cements - 3QFY17 Result Update - Healthy Operating Performance Continues amid Realizations Pressure - Reliance Securities
Hexaware Technologies - 4QCY16 Result Update - Solid Quarter, Deal Wins Strong; Client-Specific Issue A Negative - Reliance Securities
eClerx Services - 3QFY17 Result Update - Disastrous Performance on All Counts - Reliance Securities
Punjab National Bank - 3QFY17 Result Update - Asset Quality Pressure Recedes; Reiterate HOLD - Reliance Securities
HeidelbergCement India: 3QFY17 Result: FIRST CUT - Reliance Securities
Views on Lupin Limited 3QFY2017 Results: Angel Broking
Skipper - 3QFY17 Result Update - Transmission Capex Play; On Right Track - Reliance Securities
NTPC - 3QFY17 Result Update - Improving Performance on Operational Metrics - Reliance Securities
Navkar Corporation - 3QFY17 Result Update - Stable Performance; Strong Volume Growth on the Cards - Reliance Securities
Views on IPCA Laboratories Ltd 3QFY2017 Results: Angel Broking


Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2017